Brexucabtagene autoleucel shows promise in relapsed or refractory mantle cell lymphoma in routine practiceMarch 23, 2023B Cell Lymphoma
Commentary: New treatment strategies for diffuse large B-cell lymphoma, March 2023March 1, 2023B Cell Lymphoma
Diagnosis to treatment interval: A crucial prognostic factor in newly diagnosed mantle cell lymphomaFebruary 24, 2023B Cell Lymphoma
Diffuse large B-cell lymphoma: No impact of lenalidomide after R-CHOP on unfavorable prognosis of low NK-cell countsFebruary 24, 2023B Cell Lymphoma
Ibrutinib shows long-term benefits in chronic lymphocytic leukemia/small lymphocytic lymphoma in RESONATE-2February 24, 2023B Cell Lymphoma
Relapsed follicular lymphoma: Autologous stem cell transplantation shows long-term curative effectsFebruary 24, 2023B Cell Lymphoma
Second-line lisocabtagene maraleucel shows promise in large B-cell lymphomaFebruary 24, 2023B Cell Lymphoma
Mantle cell lymphoma: Real-world benefits of rituximab maintenance after first-line BR/R-CHOPFebruary 24, 2023B Cell Lymphoma
Bendamustine-rituximab effective in elderly with indolent non-Hodgkin's or mantle cell lymphomaFebruary 24, 2023B Cell Lymphoma
Glofitamab induces a durable complete response in diffuse large B-cell lymphomaFebruary 24, 2023B Cell Lymphoma
Zanubrutinib tops ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphomaFebruary 24, 2023B Cell Lymphoma
Mantle cell lymphoma: Long-term data support high-dose cytarabine-containing regimensFebruary 24, 2023B Cell Lymphoma
